However, the clinical response to TRAIL and TRAIL-based therapeutics is unsatisfactory in most cancers, with glioblastoma multiforme (GBM) being particularly resistant [11,12], defining an imperious need to thoroughly resolving the mechanisms of TRAIL resistance. This evidence concerns the gene TNFSF10 and glioblastoma.